# Molecular Profiling in Lung Cancer Patients

> **NCT00191308** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Carcinoma

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cisplatin
- **PROCEDURE:** Radical Non-Small Cell Lung Cancer (NSCLC) surgery

## Key facts

- **NCT ID:** NCT00191308
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-07
- **Final completion:** 2010-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191308, "Molecular Profiling in Lung Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*